FR2850105B1 - Moyens pour la regulation de l'expression des isoformes humaines de l'ant - Google Patents

Moyens pour la regulation de l'expression des isoformes humaines de l'ant

Info

Publication number
FR2850105B1
FR2850105B1 FR0300622A FR0300622A FR2850105B1 FR 2850105 B1 FR2850105 B1 FR 2850105B1 FR 0300622 A FR0300622 A FR 0300622A FR 0300622 A FR0300622 A FR 0300622A FR 2850105 B1 FR2850105 B1 FR 2850105B1
Authority
FR
France
Prior art keywords
ant
regulating
expression
human isoforms
isoforms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0300622A
Other languages
English (en)
Other versions
FR2850105A1 (fr
Inventor
Annie Borgne
Dominique Rebouillat
Etienne Jacotot
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Theraptosis SA
Original Assignee
Theraptosis SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theraptosis SA filed Critical Theraptosis SA
Priority to FR0300622A priority Critical patent/FR2850105B1/fr
Priority to US10/542,708 priority patent/US20060210535A1/en
Priority to EP04703813A priority patent/EP1585762A1/fr
Priority to CA002513699A priority patent/CA2513699A1/fr
Priority to PCT/FR2004/000127 priority patent/WO2004067558A1/fr
Priority to JP2006502111A priority patent/JP2007527200A/ja
Publication of FR2850105A1 publication Critical patent/FR2850105A1/fr
Application granted granted Critical
Publication of FR2850105B1 publication Critical patent/FR2850105B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
FR0300622A 2003-01-21 2003-01-21 Moyens pour la regulation de l'expression des isoformes humaines de l'ant Expired - Fee Related FR2850105B1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
FR0300622A FR2850105B1 (fr) 2003-01-21 2003-01-21 Moyens pour la regulation de l'expression des isoformes humaines de l'ant
US10/542,708 US20060210535A1 (en) 2003-01-21 2004-01-21 Means for regulating the expression of human isoforms of ant
EP04703813A EP1585762A1 (fr) 2003-01-21 2004-01-21 Moyens pour la regulation de l'expression des isoformes humaines de l'ant
CA002513699A CA2513699A1 (fr) 2003-01-21 2004-01-21 Moyens pour la regulation de l'expression des isoformes humaines de l'ant
PCT/FR2004/000127 WO2004067558A1 (fr) 2003-01-21 2004-01-21 Moyens pour la regulation de l'expression des isoformes humaines de l'ant
JP2006502111A JP2007527200A (ja) 2003-01-21 2004-01-21 ヒトａｎｔのアイソフォームの発現の調節方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0300622A FR2850105B1 (fr) 2003-01-21 2003-01-21 Moyens pour la regulation de l'expression des isoformes humaines de l'ant

Publications (2)

Publication Number Publication Date
FR2850105A1 FR2850105A1 (fr) 2004-07-23
FR2850105B1 true FR2850105B1 (fr) 2006-07-28

Family

ID=32605896

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0300622A Expired - Fee Related FR2850105B1 (fr) 2003-01-21 2003-01-21 Moyens pour la regulation de l'expression des isoformes humaines de l'ant

Country Status (6)

Country Link
US (1) US20060210535A1 (fr)
EP (1) EP1585762A1 (fr)
JP (1) JP2007527200A (fr)
CA (1) CA2513699A1 (fr)
FR (1) FR2850105B1 (fr)
WO (1) WO2004067558A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120095263A (ko) * 2011-02-18 2012-08-28 주식회사 바이오인프라 Ａｄｅｎｉｎｅ ｎｕｃｌｅｏｔｉｄｅ ｔｒａｎｓｌｏｃａｔｏｒ ２ ｍＲＮＡ 발현을 감소시켜 유방암을 치료하는 방법
US8399426B2 (en) * 2006-04-11 2013-03-19 Bioinfra Inc. Method for treating breast cancer using adenine nucleotide translocator 2 (ANT2) siRNA or ANT2 shRNA
KR20070101610A (ko) * 2006-04-11 2007-10-17 주식회사 바이오인프라 Ａｎｔ２ 유전자의 발현을 억제하는 작은 간섭 ｒｎａ를이용한 암 유전자 치료 및 항암제 내성 극복방법

Also Published As

Publication number Publication date
FR2850105A1 (fr) 2004-07-23
CA2513699A1 (fr) 2004-08-12
JP2007527200A (ja) 2007-09-27
US20060210535A1 (en) 2006-09-21
EP1585762A1 (fr) 2005-10-19
WO2004067558A1 (fr) 2004-08-12

Similar Documents

Publication Publication Date Title
IL209842A0 (en) Compounds for the treatment of metabolic disorders
IL163947A0 (en) Methods/devices for regulating patient's temperature
SI1476162T1 (sl) Nadzirana sinteza ziprasidona
FR2820312B1 (fr) Composition pulverulente pour la decoloration des fibres keratiniques humaines
FR2854074B1 (fr) Utilisation de l'ivermectine pour le traitement de desordres dermatologiques
IL162311A0 (en) N-aryl-n'-arylcycloalkyl-urea derivatives aas mch antagonists for the treatment of obesity
FR2828065B1 (fr) Composition fongicide et utilisation de cette composition pour la lutte contre les maladies des plantes
FR2824734B1 (fr) Composition pulverulente pour la decoloration des fibres keratiniques humaines
ITMI20022260A1 (it) Apparecchio per la regolazione dell'altezza di scatole di comando.
HUP0201791A3 (en) The use of escitalopram for treatment of neurotic disorders
FR2863878B1 (fr) Utilisation d'ecdysteroides pour la preparation de compositions dermathologiques ou cosmetiques anti-chute de cheveux.
NO20012106L (no) Middel for behandling av forstyrrelser i benmetabolismen
FR2850105B1 (fr) Moyens pour la regulation de l'expression des isoformes humaines de l'ant
PL375564A1 (en) Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma
EP1581209A4 (fr) Nouveaux analogues de benzopyranne et leur utilisation pour le traitement du glaucome
ITPD20020198A1 (it) Piano attrezzato richiudibile per la preparazione di sigarette
ITPD20020251A1 (it) Dispositivo per l'ottimizzazione dell'innesto di
AU2003250329A8 (en) Regulation of novel human asparagine-hydroxylases
IS2153B (is) S-nítrósóþíól til meðferðar við blóðrásartruflunum
FR2838054B1 (fr) Association d'extraits de plantes pour le traitement de la cellulite
PL371270A1 (en) Substituted 2-pyrrolidine-2-yl-1h-indole derivatives for the treatment of migraine
FR2813792B1 (fr) Moyens pour la regulation des defenses immunitaires
FR2833967B1 (fr) Utilisation de bacteries lactiques pour la production d'alpha-cetoglutarate
FR2843042B1 (fr) Dispositif pour l'adsorption controlee de l'humidite
FR2843015B1 (fr) Implant pour le traitement de la presbytie

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20100930